COMPIT

COMPIT aims to position itself in the (bio)pharmaceutical market with the development of a unique in vitro platform for the testing and prediction of the full human immune response to drugs. The system merges cutting-edge immune response testing, 3D tissue models and ultrasensitive analytical assays based on the contemporary theory
of immune response. COMPIT is outperforming current immune response testing and is complementary to current information obtained from preclinical studies.
With the advent of large molecule drugs, there is an increasing need for a better understanding of the human immune response to drugs. COMPIT will meet this demand by delivering new compelling information on the safety of drugs. COMPIT will boost the development of safer drugs and aid customers in decision making in drug development, preventing financial loss and human health hazard. Importantly the platform will be an in vitro system, thus reducing the waste in animals during drug development.